Press release

Meletios Therapeutics receives €5.2 million in funding from the European Innovation Council Accelerator for the clinical development of its candidate MLT103

- **Meletios Therapeutics was selected as one of the 75 awarded European companies of the European Commission's EIC Accelerator program, out of more than 1,000 applicants.**
- **A financing of 5.2 M€ consisting of a grant of 2.5 M€ and an equity investment of 2.7 M€ by the European Innovation Council Fund.**
- **Meletios Therapeutics is developing a new generation of broad-spectrum antiviral treatments to address the existing and emerging viral diseases. Its lead candidate, MLT103, will soon enter Phase 2 clinical development.**

Paris, France, November 2nd, 2022 – **Meletios Therapeutics**, a French biotech company specializing in the research and development of next-generation antiviral treatments, announced today that it has been named one of the 75 winners of the highly selective European Innovation Council (EIC) Accelerator program and will receive €5.2 million in funding from the European Commission.

This funding consists of a €2.5 million grant and a €2.7 million equity investment through the European Innovation Council Fund (EIC Fund). It was awarded to Meletios Therapeutics following its selection among more than 1,000 other innovative companies in all fields, as part of the Accelerator program set up by the European Commission to support and accelerate the development of European start-ups and companies at the cutting edge of innovation.

Companies selected in this program receive financial support and a range of services to accelerate their development, offering access to experts, investors, and other major players in the European ecosystem. Since its launch in March 2021, the European Innovation Council's Accelerator program has received more than 7,000 innovative project proposals, authorized more than 4,000 to submit a full application and selected 313 winners.

Meletios Therapeutics is one of the 75 companies selected among more than 1,000 applicants who submitted a complete application during the selection phase conducted in June 2022. Meletios also stands out among the 20% of awarded companies whose CEO is a woman.

“We are very pleased with this award, which is a true recognition at the European level of our teams’ expertise and of the scientific relevance of our project. Meletios Therapeutics has been committed since its creation to the development of a new generation of antiviral treatments in response to the ever-increasing emergence of new viral diseases, including the recent Covid-19," **said Catherine Martre, Chief Executive Officer of Meletios Therapeutics.** *"Obtaining this highly selective financing is a very important vote of confidence and support that will allow us to rapidly advance the clinical development phases of our compound. These steps are in line with our objective to offer a rapid and effective solution to this major global health problem. Alternatively, we are actively pursuing the development of our other candidates based on cutting-edge technologies such as the one developed at Institut Pasteur.”*

The funding will be used for the clinical development of Meletios Therapeutics' lead candidate, MLT103, and most specifically for the funding of a Phase 2 clinical trial in the treatment of SARS-CoV-2 infection as a first indication.

MLT103 is an orally administered small molecule antiviral drug that has already proven its safety in humans and can target key functions of the cell metabolism that are hijacked by viruses for replication.

MLT103 has demonstrated a dual antiviral and anti-inflammatory efficacy against the entire family of coronaviruses (including the highly pathogenic MERS, SARS-CoV-1, and SARS-CoV-2), as well as against the H1N1 influenza virus. The data available on the compound have enabled Meletios Therapeutics to validate its proposed accelerated development plan with the European Medicines Agency for entry into Phase 2 of clinical development for the treatment of Covid-19.

Meletios Therapeutics' second development program, based on a technology developed at the Institut Pasteur, aims to develop a new class of antiviral treatments based on Defective Viral Genomes (DVG). The active ingredient, an RNA sequence inspired by viral genomes, has the ability to parasitize and inhibit the replication of the virus from which it is derived. Indeed, the therapeutic RNA sequence recruits the machinery of the infectious virus at its expense. Meletios is currently industrializing this technology platform in order to launch the first tests on DVGs targeting Zika and Chikungunya viruses as soon as possible.

***

About Meletios Therapeutics: https://meletiostx.com

Founded in April 2020 in Paris by a team of top scientists and biotechnology experts, Meletios Therapeutics aims to address the urgent medical need for antiviral solutions to current and emerging diseases.

Its first drug candidate, MLT103, has confirmed its potential within *in vitro* and *in vivo* models against all coronaviruses and H1N1 influenza by acting on mechanisms and functions hijacked by the viruses in infected host cells.

Meletios Therapeutics also has a second research program using an innovative technology, licensed from Institut Pasteur, to directly interfere with the replication mechanism of RNA viruses. The potential of two candidates for the treatment of Zika and Chikungunya virus infections will soon be evaluated by the Company.

Several other drug candidates in Meletios Therapeutics' portfolio are being developed to expand the Company's antiviral pipeline.

With its unique approach and recognized expertise, Meletios Therapeutics intends to become a global leader in the fight against emerging viral infections by developing innovative, broad-spectrum therapeutic solutions capable of being active on infections related to all types of viral strains.

Media relations:

Nicolas Merigeau / Arthur Rouillé – NewCap
nmerigeau@newcap.fr / arouille@newcap.fr
+33 (0)1 44 71 94 98 / +33 (0)1 44 71 00 15